Business
New patent filing
New patent filing.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 1212E OptiBiotix Health PLC 14 July 2016 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nNew patent filing: Combination ingredients to reduce cardiovascular risk factors\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol,\ndiabetes and skin care, is pleased to announce a new patent filing. The filing protects the combination of OptiBiotix's Lactobacillus plantarum strain along with other ingredients identified by scientific key opinion leaders which act synergistically to reduce cardiovascular risk factors.\n \nThe patent filing follows on from the announcement on the 7 April 2016 relating to human studies which demonstrated 0.1g of a capsulated product has commercial potential as a safe, easy to use, low cost cholesterol reducing supplement. The filing of this patent extends OptiBiotix's protection across a broader range of market opportunities and increases the number of partnering opportunities.\n \nCurrent products for cardiovascular disease tend to focus on single risk factors, largely LDL (bad) cholesterol. However, there is a growing evidence base that suggests cardiovascular risk is a sum of a number of factors including triglycerides and blood pressure. \n \nThe novelty in the new patent filing is that when used in combination with OptiBiotix's cholesterol reducing strain the combination has the potential to:-\n \ni. Reduce multiple cardiovascular risk factors in a single presentation\nii. Enhance the overall effect on LDL reduction based on synergies in mechanism of action\niii. Reduce statin dosage mitigating possible side effects and improving patient compliance\n \nThe Company believes that filing this patent adds a further layer of protection to its intellectual property portfolio, creates a valuable asset, and broadens the number of product and partnering opportunities which now expands from consumer health to pharma.\n \nStephen O'Hara, CEO of OptiBiotix, commented: \"We are pleased to announce the filing of this patent which adds a further level of protection and value to our cholesterol and blo...